Iodide

Iodide

SCHEMBL526909

CCCCc1nccn1C.I

nearest known ligand 0.65

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG

The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.44
ALDH1A1 P00352 1/20 0.44
POLB P06746 1/20 0.44
TLR8 Q9NR97 2/20 0.42
FDPS P14324 1/20 0.41
MEN1 O00255 2/20 0.40
KCNH2 Q12809 3/20 0.39
LPO P22079 1/20 0.39
FNTA P49354 1/20 0.38
FNTB P49356 1/20 0.38
AGTR1 P30556 1/20 0.36
AGTR2 P50052 1/20 0.36
HTT P42858 1/20 0.36
APLNR P35414 1/20 0.35
DRD4 P21917 1/20 0.35
TLR7 Q9NYK1 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL40842 0.98 KMT2A (0.46) KMT2AALDH1A1POLBTLR8FDPS
Hydrochloric Acid SCHEMBL28021855 0.96 KMT2A (0.44) KMT2AALDH1A1POLBTLR8FDPS
Methane SCHEMBL28225457 0.96 KMT2A (0.44) KMT2AALDH1A1POLBTLR8FDPS
Fluoride SCHEMBL15156374 0.96 KMT2A (0.44) KMT2AALDH1A1POLBTLR8FDPS
Bromide SCHEMBL15532009 0.96 KMT2A (0.44) KMT2AALDH1A1POLBTLR8FDPS
Hydrochloric Acid SCHEMBL28330230 0.96 KMT2A (0.44) KMT2AALDH1A1POLBTLR8FDPS
Hydrochloric Acid SCHEMBL204294 0.96 TLR8 (0.44) KMT2AALDH1A1POLBTLR8FDPS
Water SCHEMBL1176982 0.96 KMT2A (0.44) KMT2AALDH1A1POLBTLR8FDPS
Bromide SCHEMBL204550 0.96 KMT2A (0.44) KMT2AALDH1A1POLBTLR8FDPS
Bromide SCHEMBL28281143 0.94 KMT2A (0.43) KMT2AALDH1A1POLBTLR8FDPS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 185 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140034869-A1 Gel Electrolytes For Dye Sensitized Solar Cells MERCK PATENT GMBH (DE) 2014-02-06 US claimed
US-8581096-B2 Gel electrolytes for dye sensitized solar cells MERCK PATENT GMBH (DE) 2013-11-12 US claimed
US-8236974-B2 Process for preparing glycidyl esters BASF SE (DE) 2012-08-07 US claimed
US-20090272934-A1 GEL ELECTROLYTES FOR DYE SENSITIZED SOLAR CELLS MERCK KGAA (DE) 2009-11-05 US claimed
JP-2005516365-A 2005-06-02 JP claimed
US-6900382-B2 Gel electrolytes for dye sensitized solar cells KONARKA TECHNOLOGIES, INC. (US) 2005-05-31 US claimed
US-20050039790-A1 Gel electrolytes for dye sensitized solar cells KONARKA TECHNOLOGIES, INC. (US) 2005-02-24 US claimed
EP-1470563-A2 PHOTOVOLTAIC CELL COMPONENTS AND MATERIALS Konarka Technologies, Inc. (US) 2004-10-27 EP claimed
US-20040025933-A1 Gel electrolytes for dye sensitized solar cells KONARKA TECHNOLOGIES, INC. (US) 2004-02-12 US claimed
WO-2003065394-A2 PHOTOVOLTAIC CELL COMPONENTS AND MATERIALS KONARKA TECHNOLOGIES, INC. (US) 2003-08-07 WO claimed
US-12540199-B2 Molding material production method and molding material SEIKO EPSON CORPORATION (JP) 2026-02-03 US disclosed
US-20240317896-A1 Molding Material Production Method And Molding Material SEIKO EPSON CORPORATION (JP) 2024-09-26 US disclosed
CN-118684785-A Method for producing molding material and molding material 精工爱普生株式会社 2024-09-24 CN disclosed
US-20230322787-A1 PROCESS FOR PREPARING ENANTIOMERICALLY ENRICHED JAK INHIBITORS SUN PHARMACEUTICAL INDUSTRIES, INC. 2023-10-12 US disclosed
EP-4196481-A1 PROCESS FOR PREPARING ENANTIOMERICALLY ENRICHED JAK INHIBITORS Concert Pharmaceuticals Inc. (US) 2023-06-21 EP disclosed
US-20030188776-A1 Photovoltaic powered multimedia greeting cards and smart cards KONARKA TECHNOLOGIES, INC. 2003-10-09 US disclosed
WO-2003065393-A2 DISPLAYS WITH INTEGRATED PHOTOVOLTAIC CELLS KONARKA TECHNOLOGIES, INC. (US) 2003-08-07 WO disclosed
WO-2003065471-A2 PHOTOVOLTAIC FIBERS KONARKA TECHNOLOGIES, INC. (US) 2003-08-07 WO disclosed
WO-2003065394-A2 PHOTOVOLTAIC CELL COMPONENTS AND MATERIALS KONARKA TECHNOLOGIES, INC. (US) 2003-08-07 WO disclosed
WO-2003065472-A2 STRUCTURES AND MATERIALS FOR DYE SENSITIZED SOLAR CELLS KONARKA TECHNOLOGIES, INC. (US) 2003-08-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12540199-B2 Molding material production method and molding material ACP1, RPL28, PLIN3 KMT2A 996/4885ALDH1A1 2881/4885POLB 2598/4885
US-20230322787-A1 PROCESS FOR PREPARING ENANTIOMERICALLY ENRICHED JAK INHIBITORS JAK1, JAK3, JAK2 KMT2A 1188/4885ALDH1A1 2276/4885POLB 1850/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.